EBA
REGN icon

Eagle Bay Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Eagle Bay Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80
Closed -$84.1K – 1033
2024
Q3 		$84.1K Sell
80
-1
-1% -$1.11K 0.03% 345
2024
Q2 		$85.1K Sell
81
-1
-1% -$969 0.05% 256
2024
Q1 		$78.9K Sell
82
-2
-2% -$1.9K 0.05% 247
2023
Q4 		$73.8K Sell
84
-1
-1% -$823 0.05% 250
2023
Q3 		$70K Sell
85
-1
-1% -$786 0.03% 337
2023
Q2 		$61.8K Buy
86
+2
+2% +$1.54K 0.04% 329
2023
Q1 		$69K Sell
84
-5
-6% -$3.77K 0.04% 316
2022
Q4 		$64.2K Sell
89
-7
-7% -$5.17K 0.04% 326
2022
Q3 		$66K Sell
96
-6
-6% -$3.78K 0.04% 288
2022
Q2 		$60.3K Buy
+102
New +$66.3K 0.04% 319
2022
Q1 		– Sell
-109
Closed -$69K – 814
2021
Q4 		$69K Sell
109
-102
-48% -$62.7K 0.04% 274
2021
Q3 		$128K Buy
211
+105
+99% +$65.2K 0.07% 193
2021
Q2 		$61K Buy
+106
New +$53.7K 0.05% 275

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eagle Bay Advisors's REGN Position: Q4 2024 in Review

Eagle Bay Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 80 shares — an estimated $84.1K sold.

Eagle Bay Advisors first reported a position in REGN in Q2 2021 and held it in 13 quarters. The position peaked at $128K in Q3 2021. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Eagle Bay Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Eagle Bay Advisors sold 80 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $84.1K.
  • Eagle Bay Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 13 quarters.
  • Eagle Bay Advisors's Regeneron Pharmaceuticals position peaked at $128K in Q3 2021.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Eagle Bay Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.